http://oxfordpharmascience.com/


Oxford Pharmascience is a drug development company that re-develops approved drugs to make them better, safer and easier to take.

Oxford Pharmascience is using its proprietary oral drug delivery technologies to develop improved formulations of non-steroidal anti-inflammatory drugs (NSAIDs) and statins for global markets.

The Company's risk-diversified pipeline of prescription and OTC medicines is focused on cardiovascular disease and pain relief indications. Since the products incorporate previously approved drugs, this reduces risk and results in a simplified drug development regulatory pathway allowing less expensive development programs and faster access to market.

The Company has also commercialized calcium/vitamin D chews that taste better and dissolve faster than currently available regular formats. These products are now marketed in the UK, Middle East and Brazil.

Oxford Pharmascience is located in the UK and is led by a highly experienced management team that directs and manages the outsourcing of its development; pre-clinical and clinical programs; and manufacturing to a trusted network of partners and suppliers.

The Company commercializes its portfolio of product opportunities through out-licensing to leading pharmaceutical companies worldwide. Currently the Company has partnerships with Aché Laboratories and Bayer.

Oxford Pharmascience (LON:OXP) was established by a team of entrepreneurs in 2008 and is a publicly listed company on London's Alternative Investment Market (AIM), with a strong blue chip investor base.

Oxford Pharmascience to develop range of safer anti-inflammatory drugs
By John Harrington May 08 2013, 3:41pm NSAIDs are one of the most widely used classes of drugs, with more than 30 million users worldwide consuming NSAIDs each dayNSAIDs are one of the most widely used classes of drugs, with more than 30 million users worldwide consuming NSAIDs each day

Wednesday’s announcement of a successful study indicating OXPzero ibuprofen could reduce stomach irritation side-effects is a step forward in an archetypal Oxford Pharmascience (LON:OXP) low-risk/high-reward programme.

While the study was only conducted on mice, the breakthrough could be significant. The genetic and biological characteristics of mice are close to those of humans, which is one of the reasons they are so widely used in medical research.

The pharmacological study showed that Oxford’s OXPzero Ibuprofen material reduces the irritation and ulcerating damage of ibuprofen.

Ibuprofen, along with the likes of aspirin and paracetamol, is one of the main “go-to” pain killers available over the counter today. It has long been proved to be effective in easing pain and swelling, and is a member of a group of medicines called non-steroidal anti-inflammatory drugs, or NSAIDs for short.

According to the NHS, ibuprofen can cause a number of side effects, including: nausea, vomiting, diarrhoea, indigestion and abdominal pain.

Less common side effects include: headache, inflammation of the stomach (gastritis), duodenal or gastric ulcers.

The results from the tests on mice, if repeated in humans, could see the irritation and ulcerating damage of ibuprofen significantly reduced.

For Oxford Pharmascience this is potentially big news.

“It could increase the number of people able to take ibuprofen, and it could enable existing users to increase the frequency of the dosage,” Oxford’s chief executive officer Nigel Theobald told Proactive Investors.

That could increase the size of the ibuprofen market, estimated to be worth US$12bn in annual sales globally, but more importantly, it could give the UK company a shot at a significant slice of this enormous market.

After all, given a choice between an ibuprofen tablet that is going to upset your tummy and possibly even cause ulcers and internal bleeding, and a product that minimises the prospect of unpleasant side effects, which are you going to choose?

OXPzero has already been used to develop ibuprofen products, including chewable tablets and suspensions, without any irritation or burn in the throat. With products created using Oxford’s technology, Mary Poppins would not need the spoonful of sugar to help the medicine go down.

The latest breakthrough is something different, though.

“This extends the OXPzero proposition beyond taste masking into the area of gastrointestinal side effects,” Theobald stressed.

Theobald said the company would now press ahead with a programme to develop a range of safer NSAIDs that are less likely to cause gastric irritation.

Following a successful fund raising in February, Oxford has the firepower to instigate this programme without having to divert resources from its other programmes, such as the highly promising cholesterol-lowering statin development.

“We’ll be able to develop in parallel, rather than in series, “ Theobald explained.

“It’s a classic example of what we do. It’s what we call re-engineering of everyday drugs that have issues. There’s nothing wrong with ibuprofen, but it has some issues, such as gastrointestinal irritation, so we want to address those.”

By focusing on drugs that have already passed all the regulatory hurdles, Oxford saves itself an enormous amount of time, energy and money. Instead of say, an uncertain journey to market that could take several years, as is the case with a new drug discovery, re-engineering an existing drug offers a safer, shorter journey to market.

“By re-developing existing drugs to make them safer or easier to take, we can access the high value returns associated with new drugs but for a fraction of the cost and with a much quicker timescale," Theobald said.

If all goes well, Oxford should have a full range of safer NSAIDs available to the market by 2016, thereby opening up the huge NSAIDs market to its reformulation technology. By full range, the company means the likes of diclofenac, naproxen and our old friend aspirin.

By any measure, that's news that is easy to stomach.

Oxford Pharmascience, up 3.97%, was wanted after it announced the results of a study on mice which showed that its OXPzero Ibuprofen material reduces the irritation and ulcerating damage of ibuprofen.

If the results are repeated in humans, then that will be great news for pain sufferers who cannot abide the side effects of taking non-steroidal anti-inflammatory drugs (NSAIDs); these include ulcers and bleeding, and in extreme cases can lead to significant poor health or even death.

The NSAIDs market is an absolutely massive one, with around US$12bn a year spent on this class of drugs. If Oxford can crack the problem of gastrointestinal side effects then the market will be even bigger, and the UK company would be set to grab a significant slice of it.

Oxford Pharmascience shares advance further on ibuprofen data
By Ian Lyall May 09 2013, 12:52pm At 1pm, the shares were changing hands for 4 pence each and their value has increased 150% in the past year. At 1pm, the shares were changing hands for 4 pence each and their value has increased 150% in the past year.

Shares in Oxford Pharmascience (LON:OXP) advanced a further 2% on Thursday and built on Wednesday’s gains as the market continued to digest data on its safer iteration of a top selling painkiller.

OXP’s study indicated its OXPzero Ibuprofen could reduce stomach irritation side-effects.

While the research was only conducted on mice, the breakthrough could be significant.

The genetic and biological characteristics of mice are close to those of humans, which is one of the reasons they are so widely used in medical research.

The pharmacological assessment showed that Oxford’s OXPzero Ibuprofen material reduces the irritation and ulcerating damage of ibuprofen.

Broker N+1 Singer said the results were a “very significant and important” step for the group and added that that OXP product had “remarkable potential”.

“There are over 30 million people consuming NASIDs (non-steroidal anti-inflammatory drugs) every day, generating around US$12 billion in annual sales, providing a very attractive opportunity to the group,” said analyst Sheena Berry.

“We note the impressive share price performance over the last seven months and believe this momentum should continue as the company progresses its programmes through development.”

At 1pm, the shares were changing hands for 4 pence each and their value has increased 150% in the past year.

Some large O trade buys this afternoon and the share price hasn't budged.

proactive investor -

Shares in Oxford Pharmascience (LON:OXP) advanced almost 20% this week as it revealed data on its safer version of a top selling painkiller.

OXP’s study indicated its OXPzero Ibuprofen could reduce stomach irritation side-effects. And although the research was only conducted on mice, the breakthrough could be significant.

Target price raised to 9.2p:

Oxford Pharmascience price target raised 33% by N+1 Singer
By Ian Lyall May 15 2013, 1:56pm

According to the NHS, ibuprofen can cause a number of side effects, including nausea, vomiting, diarrhoea, indigestion and abdominal pain.

City broker N+1 Singer has raised its valuation of Oxford Pharmascience (LON:OXP) by 33% to reflect the potential of its adaptation of a top selling painkiller.

Its target price rises to 9.2 pence a share, representing a significant premium to the current share price of 3.92 pence.

The upgrade follows pre-clinical data last week that indicated OXPzero ibuprofen could reduce stomach irritation side-effects.

While the study was only conducted on mice, the breakthrough could be significant.

The genetic and biological characteristics of mice are close to those of humans, which is one of the reasons they are so widely used in medical research.

The pharmacological trial showed that Oxford’s OXPzero Ibuprofen material reduces the irritation and ulcerating damage of ibuprofen.

Ibuprofen, along with the likes of aspirin and paracetamol, is one of the main “go-to” pain killers available over the counter today.

It has long been proved to be effective in easing pain and swelling, and is a member of a group of medicines called non-steroidal anti-inflammatory drugs, or NSAIDs for short.

According to the NHS, ibuprofen can cause a number of side effects, including nausea, vomiting, diarrhoea, indigestion and abdominal pain.

“The successful data from the proof of concept pre-clinical trial is a very significant and important step for the group,” said N+1 analyst Sheena Berry.

“The initiation of the NSAIDs programme is very interesting and one that could be very rewarding given the size of the US$12bn NSAIDs market.

“The change in focus to the higher value pharmaceutical market in 2011 is proving to have been a pivotal decision and one, in our view, that has the potential to reap significant benefits.”

Since hitting a low in September last year the stock advanced more than 330%, but is still valued at less than £30mln.

However, analyst Berry remains optimistic on the outlook for the stock.

“We continue to be extremely upbeat about the group as it continues its drive to become a major player in the re-formulation market,” she added.

Good news d ,9.2p

The drinks are on you then when that happens dc - I would like a nicely chilled glass of Sancerre, thank you !:-)

Lol, have what ever you would like d.

Hitting an all time high right now.

Oxford Pharmascience Group PLC (OXP:LSE) set a new 52-week high during today's trading session when it reached 4.30. Over this period, the share price is up 214.81%.

10million 'O' trade just gone through at 4.125p

Some big trades going through after the close tonight.

Bodes well d4. :-))


Oxford Pharma brings new life to tried and tested drugs
By Proactive Investors May 22 2013, 8:45am
Marcelo Bravo, Chief Technology Officer at Oxford Pharmascience (LON:OXP), explains to Proactiveinvestors how the company re-engineers existing drugs to improve the way they work and overcome side effects. Marcelo discusses the recent successful study for ibuprofen and the launch of the safer NSAID programme, the news of which drove shares to two year highs.


http://www.proactiveinvestors.co.uk/companies/stocktube/2001/oxford-pharma-brings-new-life-to-tried-and-tested-drugs-2001.html

2 RNS just out - Invesco picked up another 20 million shares earlier this week.

Holding(s) in Company

RNS

UBS Investment Bank



http://www.moneyam.com/action/news/showArticle?id=4603160

10million buy declared at 18.26.

2 RNS just out. UBS increasing their holding.

Ache Line Extension

RNS


RNS Number : 1350G

Oxford Pharmascience Group PLC

04 June 2013




Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Oxford Pharmascience announces line extension for Brazil



Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to make medicines better, safer and easier to take, today announces that it has agreed a line extension in Brazil with its Brazilian partner Aché Pharmaceuticos (Aché) for a new version of its calcium and vitamin D chew marketed under the brand name Inellare.

Sales to Aché of this new format are expected to begin in Q3 2013.



Nigel Theobald, Chief Executive Officer of Oxford Pharmascience commented,

"Our chew business in Brazil continues to grow strongly and the addition of a new version of our calcium product in the Brazilian market shows both the commitment of our partner and the ongoing potential for the range."

Oxford Pharmascience (LON:OXP), which specialises in reformulating tried and tested medicines, has agreed a line extension in Brazil with its Brazilian partner Aché Pharmaceuticos.

The deal is for a new version of Oxford’s calcium and vitamin D chew marketed under the brand name Inellare.

Broker N+1 Singer speculated that the new line being introduced is a sugar-free version of the calcium and vitamin D chew.

As it had already forecast this development, it is making no changes to its estimates, adding that it expects both the sugar and sugar-free versions of the chew to achieve modest growth, with minimal cannibalisation of market share.

“This morning’s news is evidence of Oxford Pharmascience continuing to deliver, with on-going progress being made in all three of its technology platforms,” it said.

“We maintain upbeat about the group and believe it is capable of becoming a major player in the re-formulation market. We recently upgraded our intrinsic value per share to 9.2p on the back of the successful proof of concept data with OXP zero and await further updates on the group’s development progression.”